StocktoriaGRI Bio, Inc. GRI
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | — | — | — | $0 |
| Operating income | -$12.0M | -$8.2M | -$11.4M | -$2.2M | -$9.3M |
| Net income | -$12.0M | -$8.2M | -$13.0M | -$3.2M | -$9.3M |
| Operating cash flow | -$10.2M | -$8.6M | -$9.0M | -$1.1M | -$8.3M |
| Free cash flow | -$10.2M | -$8.6M | -$9.0M | -$1.1M | -$8.3M |
| Total assets | $8.7M | $5.7M | $3.0M | $383,000 | $8.3M |
| Total liabilities | $2.7M | $1.7M | $2.7M | $2.0M | $2.5M |
| Shareholders' equity | $6.0M | $4.0M | $259,000 | -$1.6M | -$4.8M |
| Ratios | |||||
| Return on assets | -138.0% | -143.0% | -441.0% | -839.9% | -111.6% |
| Return on equity | -199.0% | -203.5% | -5033.6% | 198.0% | 191.9% |
| Current ratio | 3.25 | 3.43 | 1.09 | 0.16 | 3.32 |
| Revenue growth | — | — | — | — | -100.0% |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001824293 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.